We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00986076
Recruitment Status : Completed
First Posted : September 29, 2009
Last Update Posted : September 29, 2009
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine if intraocular infusion of low-molecular weight heparin (enoxaparin) influences postoperative inflammation following pediatric cataract surgery with intraocular lens (IOL) implantation.

Condition or disease Intervention/treatment Phase
Inflammation Drug: Enoxaparin Drug: Balanced Salt Solution Phase 4

Detailed Description:

Despite advances in cataract surgery in children, postoperative inflammation is a significant complication following pediatric cataract surgery. Any drug that prevents or decreases this inflammation would be beneficial.

Heparin has anti-inflammatory and antiproliferative effects as well as anticoagulant properties. Several studies on animal and adult human eyes show that adding heparin to the irrigating solution during cataract surgery results in less disturbance of the blood-aqueous barrier and helps prevent posterior capsule opacification (PCO).

A prospective, randomized, controlled and masked study is mandatory to evaluate the anti-inflammatory effect of Low-molecular weight Heparin for pediatric cataract surgery

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery
Study Start Date : March 2008
Primary Completion Date : April 2009
Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Enoxaparin infusion

Congenital Cataract Surgery with IOL implantation

Intraocular infusion of Enoxaparin

Drug: Enoxaparin
Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
Other Name: Clexane(Aventis)
Placebo Comparator: Balanced Salt Solution Infusion
Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
Drug: Balanced Salt Solution
Intraocular infusion of Balanced Salt solution
Other Name: BSS

Outcome Measures

Primary Outcome Measures :
  1. Anterior Segment Inflammation [ Time Frame: 1 week ]

Secondary Outcome Measures :
  1. Anterior Segment inflammation [ Time Frame: 1 month, 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children (0-15 years) with congenital cataract scheduled for surgery with IOL implantation and informed consent from the parents/legal guardian

Exclusion Criteria:

  • Preoperative: Associated ocular anomalies (uveitis, microphthalmos, persistent fetal vasculature, aniridia, glaucoma, iris coloboma), traumatic cataract
  • Intraoperative: Inability to implant IOL in the capsular bag, intraoperative complications- iris trauma, vitreous disturbance, descemet's detachment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986076

Iladevi Cataract & IOL Research Centre
Ahmedabad, Gujarat, India, 380052
Sponsors and Collaborators
Iladevi Cataract and IOL Research Center
Principal Investigator: Viraj A Vasavada, MS Iladevi Cataract & IOL Research Centre
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Viraj A. Vasavada, MS, Iladevi Cataract & IOL Research Centre
ClinicalTrials.gov Identifier: NCT00986076     History of Changes
Other Study ID Numbers: 08-010
First Posted: September 29, 2009    Key Record Dates
Last Update Posted: September 29, 2009
Last Verified: September 2009

Keywords provided by Iladevi Cataract and IOL Research Center:
Pediatric Cataract Surgery
Low-Molecular weight Heparin
Intraocular infusion
Anti-inflammatory effect

Additional relevant MeSH terms:
Pathologic Processes
Lens Diseases
Eye Diseases
Pharmaceutical Solutions
Calcium heparin
Heparin, Low-Molecular-Weight
Anti-Inflammatory Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action